CHICAGO, Illinois – Scott Dillingham is always on the run.
"Most of my life revolves around family activities and that family includes two very active daughters and two very active dogs."
But living with Inflammatory Bowel Disease (IBD) for nearly 25 years has had him always running to the bathroom.
"I suddenly found myself experiencing pretty dramatic symptoms, like urgency and blood and was really quite scared."
About 3.1 million people in the U.S. are living with Inflammatory Bowel Disease, or IBD.
So what happens when that barrier breaks down?
"Then our immune system reacts to it and may think that's it under attack," explained Dr. David Rubin of the University of CHicago.
"So if you can use this small molecule almost like a key to block that enzyme from breaking down the barrier, you can actually enhance or protect that barrier."
And prevent IBD and relapses.
For Scott who takes immuno-suppressants to keep his symptoms at bay, the discovery is terrific news.
"Immuno-suppressants leave you exposed to all sorts of other complications down the road," he said.
"Being untethered from that dependency would be life-changing."
Dr. Rubin says the application is still being developed. It could be topical or could circulate in the bloodstream.
"I mean by topically is that we use a delivery system in a capsule or a tablet where it won't release the molecule until it gets all the way down into the intestine where it's needed," he said.
"There are ways we do that now with some of our other anti-inflammatory treatments. So, if it works more on the lining of the bowel maybe that's a better way to deliver this molecule- to get it in by having it released on the surface of the intestine where it can work better.'
The researchers say using the divertin molecule to enhance the intestinal barrier may also help with other diseases, such as celiac disease, graft versus host disease, and multiple sclerosis.
If this story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Jim Mertens at firstname.lastname@example.org or Marjorie Bekaert Thomas at email@example.com.